The aim of our study was to evaluate obstetric outcome of women affected by idiopathic infertility showing persistently positive antiphospholipid antibodies (aPL).
Methods
: From 2000 consecutive patients undergoing ART, we selected 151 (7.55%) clinical records of patients affected by idiopathic infertility undergoing ICSI and showing positive aPL.
Results
Persistently positive aPL were found in 64/151 (42.38%) of the patients: in 34/64 (53.12%) at medium/high titers (group A) and in 30/64 (46.87%) at low titers (group B). Primary or secondary antiphospholipid syndrome (APS) was diagnosed in 25% of the patients, whereas 37.5% women showed clinical and/or laboratory features suggestive of APS, but not fulfilling clinical or laboratory classification criteria. Idiopathic infertility was the sole symptom in 31.25%. In 55% of these infertile patients, a history of recurrent failures of assisted reproductive techniques (ART) was also observed. Eighty-eight percent (88.88%) of women became pregnant and 77.77% gave birth. During pregnancy, an increase of aPL values was observed in 29.41% women of group B.
Conclusions
A careful selection of patients allowed us to confirm that women affected by idiopathic infertility show a high prevalence of aPL, suggesting that these autoantibodies can also affect conception. Considering pregnancy complications and thrombotic risk related to ovarian stimulation, measuring aPL can represent a valid tool to identify among infertile women undergoing ART those at higher risk of pregnancy complications potentially life-threatening for mother and the fetus. In such patients, an accurate diagnosis and an adequate therapy are related to a better ART outcome.
MiyakisSLockshinMDAtsumiT, et al.International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006; 4: 295–306. DOI: 10.1111/j.1538-7836.2006.01753.x.
2.
de JesúsGRBensonAEChighizolaCB, et al.16th international congress on antiphospholipid antibodies task force report on obstetric antiphospholipid syndrome. Lupus2020; 29: 1601–1615. DOI: 10.1177/0961203320954520.
3.
de JesúsGRBensonAE.ChighizolaCB, et al.16th international congress on antiphospholipid antibodies task force report on obstetric antiphospholipid syndrome. Lupus2020; 29: 1601–1615. DOI: 10.1177/0961203320954520.
4.
BeltagyATrespidiLGerosaM, et al.Anti‐phospholipid antibodies and reproductive failures. Am J Reprod Immunol2021; 85: e13258. DOI: 10.1111/aji.13258.
5.
TektonidouMGAndreoliLLimperM, et al.EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis2019; 78: 1296–1304. DOI: 10.1136/annrheumdis-2019-215213.
6.
RuffattiAOlivieriSTonelloM, et al.Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification. J Thromb Haemost2008; 6: 1693–1696. DOI: 10.1111/j.1538-7836.2008.03121.x.
7.
El HasbaniGKhamashtaMUthmanI. Antiphospholipid syndrome and infertility. Lupus2020; 29: 105–117. DOI: 10.1177/0961203319893763.
8.
BuckinghamKLChamleyLW. A critical assessment of the role of antiphospholipid antibodies in infertility. J Reprod Immunol2009; 80: 132–145. DOI: 10.1016/j.jri.2008.11.005.
9.
KhizroevaJNalliCBitsadzeV, et al.Infertility in women with systemic autoimmune diseases. Best Pract Res Clin Endocrinol Metab2019; 33: 101369. DOI: 10.1016/j.beem.2019.101369.
10.
Alijotas-ReigJEsteve-ValverdeEFerrer-OliverasR, et al.Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from the EUROAPS registry. Rheumatology2020; 59: 1306–1314. DOI: 10.1093/rheumatology/kez419.
11.
Di RosaRFerreroSCifaniN, et al.In vitro fertilization and autoimmunity: evidence from an observational study. Eur J Obstet Gynecol Reprod Biol2019; 234: 137–142. DOI: 10.1016/j.ejogrb.2018.12.042.
12.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725. DOI: 10.1002/art.1780400928.
13.
TanEMCohenASFriesJF, et al.The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271–1277. DOI: 10.1002/art.1780251101.
14.
PetriMOrbaiAMAlarcónGS, et al.Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheumatism2012; 64: 2677–86. DOI: 10.1002/art.34473.
15.
BombardierCGladmanDDUrowitzMB, et al.Derivation of the sledai. A disease activity index for lupus patients. Arthritis Rheum1992; 35: 630–640. DOI: 10.1002/art.1780350606.
16.
MoscaMTaniCVagnaniS, et al.The diagnosis and classification of undifferentiated connective tissue diseases. J Autoimmun2014; 48-49: 50–52. DOI: 10.1016/j.jaut.2014.01.019.
17.
ShiboskiCHShiboskiSCSerorR, et al.2016 American college of rheumatology/European league against rheumatism classification criteria for primary Sjögren's syndrome. Ann Rheum Dis2017; 76: 9–16. DOI: 10.1136/annrheumdis-2016-210571.
18.
AndreoliLBertsiasGKAgmon-LevinN, et al.EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis2017; 76: 476–485. DOI: 10.1136/annrheumdis-2016-209770.
19.
ProiettaMFerreroSDel PortoF. Prevalence of antiphospholipid antibodies in patients with sterility undergoing 'in vitro' fertilization. Lupus2014; 23: 724–725. DOI: 10.1177/0961203314525865.
20.
SammaritanoLRBermasBLChakravartyEE, et al.2020 American college of rheumatology guideline for the management of reproductive health in rheumatic and nusculoskeletal diseases. Arthritis Rheumatol2020; 72: 529–556. DOI: 10.1002/art.41191.
21.
SimopoulouMSfakianoudisKMaziotisE, et al.The impact of autoantibodies on IVF treatment and outcome: a systematic review. Int J Mol Sci2019; 20: 892. DOI: 10.3390/ijms20040892.
22.
GinerVOltraMREstebanMJ, et al.Catastrophic antiphospholipid syndrome related to severe ovarian hyperstimulation. Clin Rheumatol2007; 26: 991–993. DOI: 10.1007/s10067-006-0231-4.
23.
DeguchiMYamadaHSugiura-OgasawaraM, et al.Factors associated with adverse pregnancy outcomes in women with antiphospholipid syndrome: a multicenter study. J Reprod Immunol2017; 122: 21–27. DOI: 10.1016/j.jri.2017.08.001.
24.
YetmanDLKuttehWH. Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies. Fertil Sterility1996; 66: 540–546.
25.
YelnikCMPorterTFBranchDW, et al.Brief report: changes in antiphospholipid antibody titers during pregnancy: effects on pregnancy outcomes. Arthritis Rheumatol2016; 68: 1964–1969. DOI: 10.1002/art.39668.
26.
ToppingJQuenbySFarquharsonR, et al.Marked variation in antiphospholipid antibodies during pregnancy: relationships to pregnancy outcome. Hum Reprod1999; 14: 224–228. DOI: 10.1093/humrep/14.1.224.
27.
Salazar-PáramoMJaraLJRamosA, et al.Longitudinal study of antinuclear and anticardiolipin antibodies in pregnant women with systemic lupus erythematosus and antiphospholipid syndrome. Rheumatol Int2002; 22: 142–147. DOI: 10.1007/s00296-002-0207-x.
28.
LynchARutledgeJStephensJ, et al.Longitudinal measurement of anticardiolipin antibodies during normal pregnancy: a prospective study. Lupus1995; 4: 365–369. DOI: 10.1177/096120339500400506.
29.
ProiettaMFerreroSFerriL, et al.Recurrent miscarriages in women not fulfilling classification criteria for antiphospholipid antibody syndrome. Int J Immunopathol Pharmacol2014; 27: 429–432. DOI: 10.1177/039463201402700313.
30.
LazzaroniMGFrediMAndreoliL, et al.Triple antiphospholipid (aPL) antibodies positivity is associated with pregnancy complications in aPL carriers: a multicenter study on 62 pregnancies. Front Immunol2019; 10: 1948. DOI: 10.3389/fimmu.2019.01948.
31.
PregnolatoFGerosaMRaimondoMG, et al.EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of criteria anti-phospholipid antibodies. Rheumatology (Oxford)2021; 60(3): 1114–1124. DOI: 10.101093/rheumatology/keaa203.
32.
TanXDingJPuD, et al.Anti-phospholipid antibody may reduce endometrial receptivity during the window of embryo implantation. J Gynecol Obstet Hum Reprod2021; 50: 101912. DOI: 10.1016/j.jogoh.2020.101912.
33.
YingYZhongYPZhouCQ, et al.A retrospective study on IVF outcome in patients with anticardiolipin antibody: effects of methylprednisolone plus low-dose aspirin adjuvant treatment. J Reprod Immunol2012; 94: 196–201. DOI: 10.1016/j.jri.2012.04.002.
34.
LatinoJOUdrySArandaFM, et al.Pregnancy failure in patients with obstetric antiphospholipid syndrome with conventional treatment: the influence of a triple positive antibody profile. Lupus2017; 26: 983–988. DOI: 10.1177/0961203317692432.
